Indications
Repatha® is indicated:
  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
  • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

Get in touch.
Stay connected.


Please note: This form is intended for US healthcare professionals only.

If you are a Repatha® patient, please visit RepathaReady® or call 1-844-REPATHA for support.

message.png

Whether you have product-related questions or need Repatha® samples, Repatha® Sales Representatives are here to help you and your office staff.

First Name

Enter first name

Last Name

Enter last name

Email

Enter email address

Zip Code

Enter zip code

I am a...

Select your title

NPI#

NPI#

To report an adverse event, please call 1-800-77-AMGEN (1-800-772-6436).

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit www.amgen.com/privacy.

Thank you.


Submit

REPATHA® DOSING

2 choices. Every 2 weeks or once a month. No titration

If patients require assistance, they can enroll in the RepathaReady  ® program,
where nurse support is available by phone or video conference.*

Call 1-844-REPATHA (1-844-737-2842) SHARE
Hours of operation: 8 AM-11 PM ET

*RepathaReady  ® Nurses are nurses by training and are there to provide patients and caregivers with helpful information regarding their treatment plan. They do not provide medical advice or case management services.

Repatha® offers your patients the flexibility of a single monthly injection or an injection every 2 weeks.1

Repatha® SureClick® Prefilled Autoinjector Pen

Every 2 weeks

Repatha® SureClick®


Single-use prefilled autoinjector

  • 140 mg/mL subcutaneous injection
  • Hidden 27-gauge needle
  • Delivers the 140-mg/mL dose subcutaneously up to 15 seconds

Consider the SureClick® autoinjector for patients who are comfortable self-injecting with a hand-held device.

 

 

 

How to use Repatha® SureClick®


Watch Demo


Download the Instructions for Use.


Download

Repatha® Pushtronex® Prefilled Cartridge

Once a month

Repatha® Pushtronex® System


Single-use on-body infusor with prefilled cartridge

  • 420 mg/3.5 mL subcutaneous injection
  • Hidden 29-gauge needle
  • Steady delivery of the 420-mg/3.5-mL dose subcutaneously up to 9 minutes

The Pushtronex® system securely adheres to the body for hands-free administration while patients perform activities requiring moderate exertion.


After one push of a button, the on-body device does the work.


How to use Repatha® Pushtronex® System


Watch Demo


Download the Instructions for Use.


Download

​
On-demand opinion leader video

SHORT: Injection Testimonial

"The fact that I can do an injection myself ... is so convenient for me."

​

Feel confident your patients can administer Repatha® with either delivery option

  • Built-in audible and visual cues to signal when the full dose has been delivered2
  • 95% of patients successfully administered at home with either device2*†

*Patients who reported 2 full-dose administrations of Repatha® at weeks 4 and 8. Patients received training from healthcare professionals on how to self-administer.2

†Patients used the Pushtronex® system or 3 autoinjectors for the once-monthly regimen.2

 

 

If patients require assistance, they can enroll in the RepathaReady® program,
where nurse support is available by phone or video conference.*

Call 1-844-REPATHA (1-844-737-2842) SHARE
Hours of operation: 8 AM-11 PM ET

*RepathaReady® Nurses are nurses by training and are there to provide patients and caregivers with helpful information regarding their treatment plan. They do not provide medical advice or case management services.

 

Prior to use, wait at least 30 minutes for the SureClick® autoinjector and 45 minutes for the Pushtronex® system to naturally reach room temperature in the carton.1


Do not try to warm the prefilled cartridge by using a heat source, such as hot water or a microwave. If the prefilled cartridge has been warmed with a heat source, use a new onbody infusor and prefilled cartridge and call 1-844-REPATHA (844-737-2842) or visit www.Repatha.com.1

Using the SureClick® Autoinjector

Using the Pushtronex® System

References: 1. Repatha® (evolocumab) prescribing information, Amgen. 2. Dent R, Joshi R, Djedjos CS, et al. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. SpringerPlus. 2016:5;300. doi:10.1186/s40064-016-1892-3

test

CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction.

LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction.

ACS = acute coronary syndrome; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; PCSK9 = proprotein convertase subtilisin/kexin type 9.

Reference: 1. Repatha® (evolocumab) prescribing information, Amgen.


Back to top
INDICATIONSRepatha® is indicated:
  • In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
  • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C
IMPORTANT SAFETY INFORMATION

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

test
Back to top

IMPORTANT SAFETY INFORMATION

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.